BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3089171)

  • 1. [Anti-cancer treatment with prostaglandin synthetase inhibitor in animal models].
    Narisawa T; Takahashi M; Masuda T; Nagasawa O; Ogata N; Niwa M
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1329-35. PubMed ID: 3089171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of the growth of a murine transplantable tumor, colon 26, by the prostaglandin synthetase inhibitor, indomethacin].
    Takahashi M; Narisawa T; Masuda T; Nagasawa O; Suzuki K; Yoshioka H; Koyama H
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2334-40. PubMed ID: 3111384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of peritoneal carcinomatosis recurrence with a prostaglandin synthesis inhibitor, indomethacin].
    Narisawa T; Takahashi M; Masuda T; Nagasawa O; Koyama H
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2496-501. PubMed ID: 3476022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors.
    Cahlin C; Gelin J; Andersson M; Lönnroth C; Lundholm K
    Int J Oncol; 2005 Oct; 27(4):913-23. PubMed ID: 16142306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
    Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
    Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor.
    Melamed R; Rosenne E; Shakhar K; Schwartz Y; Abudarham N; Ben-Eliyahu S
    Brain Behav Immun; 2005 Mar; 19(2):114-26. PubMed ID: 15664784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor.
    Connolly JM; Liu XH; Rose DP
    Nutr Cancer; 1996; 25(3):231-40. PubMed ID: 8771566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin.
    Cai KX; Tse LY; Leung C; Tam PK; Xu R; Sham MH
    Clin Cancer Res; 2008 Feb; 14(3):939-49. PubMed ID: 18245558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice.
    Maca RD
    J Biol Response Mod; 1988 Dec; 7(6):568-80. PubMed ID: 3216222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Potent effects of the prostaglandin synthesis inhibitor indomethacin on the cellular immune response in gastrointestinal cancer patients].
    Koyama H; Narisawa T; Kodama M; Ishikawa K; Kusaka H; Yamazaki Y; Koyama K
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1027-33. PubMed ID: 2778378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522.
    Tomozawa S; Nagawa H; Tsuno N; Hatano K; Osada T; Kitayama J; Sunami E; Nita ME; Ishihara S; Yano H; Tsuruo T; Shibata Y; Muto T
    Br J Cancer; 1999 Dec; 81(8):1274-9. PubMed ID: 10604722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Avemar and Avemar + vitamin C on tumor growth and metastasis in experimental animals.
    Hidvégi M; Ráso E; Tömösközi-Farkas R; Paku S; Lapis K; Szende B
    Anticancer Res; 1998; 18(4A):2353-8. PubMed ID: 9703878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
    Roh JL; Sung MW; Kim KH
    Head Neck; 2005 Apr; 27(4):326-32. PubMed ID: 15719392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of indomethacin on human colorectal cancer cells HCT116 and SW480].
    Wang HM; Zhang GY
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Feb; 29(1):28-31. PubMed ID: 16136999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
    Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.